| **Author, Year** | **Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?** | **Were the groups comparable  at baseline  on key prognostic factors (e.g., by restriction or matching)?** | **Did the study maintain comparable groups through the study period?** | **Did the study use accurate methods for ascertaining exposures and potential confounders?** | **Were outcome assessors and/or data analysts blinded to the exposure being studied?** | **Did the article report attrition?** | **Did the study perform appropriate statistical analyses on potential confounders?** | **Is there important differential loss to followup or overall high loss to followup?** | **Were outcomes prespecified and defined, and ascertained  using accurate methods?** | **Quality rating** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Chang 2018108 | Yes | No (some variables, such as pregnancy) | Yes | Yes | No | Yes | Yes | Differential: yes; high overall: yes, for NVP group | Yes | Fair |
| Nkhoma, 2016106 | Yes | No, significant differences for some variables | No | Yes | Unclear | No | Yes | Unclear | Yes | Fair |
| Nkhoma 2016b120 | Yes | No; differences in baseline concomitant medications used | No | Yes | Unclear | No | Yes | Unclear | Yes | Fair |

Abbreviation: NVP=nevirapine.